GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

51

Hypertension Accelerates Liver Disease Progression in MASLD- AJG Feb.26

Introduction Metabolically–dysfunction–associated steatotic liver disease (MASLD) frequently coexists with hypertension, yet blood pressure has traditionally been viewed mainly through a cardiovascular lens. Whether hypertension directly influences liver disease...

52

ANTICIPATE-NASH Beats Biopsy for Event Risk in MASLD- Gastroenterology Feb.26

Introduction In metabolic dysfunction-associated steatotic liver disease (MASLD), fibrosis stage on liver biopsy (F3 vs F4) remains the cornerstone for prognosis, surveillance, and clinical trial eligibility. However, real-world...

53

Noninvasive markers and Prediction of treatment with Semaglutide (AP&T) - Jan,2026

As of my training cut-off in October 2023, I do not have access to specific information about a publication titled "Noninvasive markers and Prediction of treatment with Semaglutide...

54

HCC Risk Prediction in Chronic HBV With Metabolic Dysfunction

Hepatocellular carcinoma (HCC) risk prediction in patients with chronic hepatitis B virus (HBV) infection who also have metabolic dysfunction is a complex but crucial aspect of clinical care....

55

Phase III Trial of Norursodeoxycholic Acid in MASLD

The Phase III trial of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) was designed to evaluate the efficacy and safety of this promising therapeutic option in...

56

FIB-4 as a Referral Index for Coronary Artery Calcification in MASLD

The Fibrosis-4 (FIB-4) index has emerged as a potentially valuable tool for assessing the risk of coronary artery calcification (CAC) in individuals with metabolic dysfunction-associated steatotic liver disease...

57

Semaglutide for MASLD: AASLD Practice Guidance November 2025

As of my knowledge cutoff in October 2023, I cannot provide specific details about the AASLD Practice Guidance from November 2025 regarding semaglutide for MASLD (metabolic dysfunction-associated steatotic...

58

M-ACCEL trial

The M-ACCEL trial is a phase IIa study that evaluated the investigational oral drug HU6 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to assess...

59

The ELMWOOD- Phase II trial

The ELMWOOD Phase II trial is a clinical study evaluating the efficacy and safety of elafibranor (brand name Iqirvo) for the treatment of primary sclerosing cholangitis (PSC). PSC...

60

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist

GLP-1 Receptor Agonist Overview A GLP-1 receptor agonist is a type of medication that mimics the action of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 is a naturally occurring...

Previous
15679
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer